- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.22 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.3: 5 residues within 4Å:- Chain A: S.6, P.8, Y.23, E.35, N.36
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:P.8
- Hydrogen bonds: A:Y.23, A:E.35
- Water bridges: A:P.8, A:N.36
NAG.4: 6 residues within 4Å:- Chain A: K.374, Q.375, N.379, S.381, I.382, E.385
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:N.379
NAG.9: 4 residues within 4Å:- Chain B: S.6, Y.23, E.35, N.36
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:Y.23, B:E.35, B:N.36
NAG.10: 5 residues within 4Å:- Chain B: K.374, Q.375, N.379, S.381, I.382
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:N.379
- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
HEM.5: 20 residues within 4Å:- Chain A: Y.117, A.168, A.171, Q.172, H.176, F.179, K.180, T.181, H.183, V.264, N.351, Y.354, H.355, W.356, H.357, L.359, L.360, F.364, L.377, V.416
21 PLIP interactions:21 interactions with chain A,- Hydrophobic interactions: A:A.171, A:Q.172, A:Q.172, A:F.179, A:V.264, A:W.356, A:L.359, A:L.360, A:F.364, A:L.377, A:V.416, A:V.416
- Hydrogen bonds: A:Y.117, A:T.181, A:N.351, A:N.351
- Water bridges: A:T.181
- Salt bridges: A:H.183
- pi-Stacking: A:H.176, A:H.355
- Metal complexes: A:H.357
HEM.11: 20 residues within 4Å:- Chain B: Y.117, A.168, A.171, Q.172, H.176, F.179, K.180, T.181, H.183, V.264, N.351, Y.354, H.355, W.356, H.357, L.359, L.360, F.364, L.377, V.416
19 PLIP interactions:19 interactions with chain B,- Hydrophobic interactions: B:A.171, B:Q.172, B:Q.172, B:F.179, B:V.264, B:W.356, B:L.359, B:L.360, B:F.364, B:L.377, B:V.416, B:V.416
- Hydrogen bonds: B:Y.117, B:T.181, B:N.351, B:N.351
- Salt bridges: B:H.183
- pi-Stacking: B:H.176
- Metal complexes: B:H.357
- 2 x L7M: 2-[1-(4-chlorobenzene-1-carbonyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-[4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)butyl]acetamide(Non-covalent)
L7M.6: 24 residues within 4Å:- Chain A: P.52, V.57, H.58, L.61, I.81, Y.84, V.85, S.88, R.89, V.318, L.321, S.322, Y.324, L.353, Y.354, W.356, F.487, M.491, V.492, E.493, G.495, A.496, S.499, L.500
20 PLIP interactions:20 interactions with chain A- Hydrophobic interactions: A:P.52, A:V.57, A:V.57, A:L.61, A:I.81, A:Y.84, A:V.85, A:Y.324, A:Y.354, A:W.356, A:F.487, A:V.492, A:V.492, A:L.500
- Hydrogen bonds: A:S.88, A:R.89, A:Y.324, A:Y.324, A:S.499
- Water bridges: A:R.482
L7M.12: 23 residues within 4Å:- Chain B: V.57, H.58, I.60, I.81, Y.84, V.85, S.88, R.89, V.318, L.321, S.322, Y.324, L.353, Y.354, W.356, F.487, M.491, V.492, E.493, G.495, A.496, S.499, L.500
17 PLIP interactions:17 interactions with chain B- Hydrophobic interactions: B:V.57, B:V.57, B:I.81, B:Y.84, B:V.85, B:Y.324, B:Y.354, B:W.356, B:F.487, B:V.492, B:V.492, B:L.500
- Hydrogen bonds: B:S.88, B:R.89, B:Y.324, B:S.499
- Halogen bonds: B:L.353
- 3 x BOG: octyl beta-D-glucopyranoside(Non-covalent)
BOG.7: 6 residues within 4Å:- Chain A: N.55, T.56, Y.59, I.60, K.480, P.483
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:T.56, A:Y.59, A:I.60
- Hydrogen bonds: A:N.55, A:K.480, A:K.480
BOG.8: 9 residues within 4Å:- Chain A: E.148, K.149, L.152, R.153, R.154, R.407, I.411, E.455, E.459
9 PLIP interactions:9 interactions with chain A- Hydrophobic interactions: A:L.152, A:L.152, A:I.411
- Hydrogen bonds: A:R.154, A:R.407, A:E.455, A:E.459, A:E.459
- Salt bridges: A:R.154
BOG.13: 5 residues within 4Å:- Chain B: N.55, T.56, Y.59, K.480, P.483
4 PLIP interactions:4 interactions with chain B- Hydrophobic interactions: B:T.56
- Hydrogen bonds: B:N.55, B:K.480, B:K.480
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xu, S. et al., Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site. J.Biol.Chem. (2019)
- Release Date
- 2018-11-14
- Peptides
- Prostaglandin G/H synthase 2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.22 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
- 2 x L7M: 2-[1-(4-chlorobenzene-1-carbonyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-[4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)butyl]acetamide(Non-covalent)
- 3 x BOG: octyl beta-D-glucopyranoside(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xu, S. et al., Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site. J.Biol.Chem. (2019)
- Release Date
- 2018-11-14
- Peptides
- Prostaglandin G/H synthase 2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B